HDi® Advanced IVUS Webinar


Dear Colleagues and Partners,

With pleasure we announce the second ACIST HDi Advanced IVUS Webinar from Erasmus Medical Center, Rotterdam, the Netherlands on Thursday 22 April, 17:00-18:00 CET.

This workshop event is an interactive educational program that is designed for physicians who want to further develop their intravascular ultrasound skills with a specific focus on step-by-step HDi IVUS Guided PCI using the HDi IVUS HD imaging technology.

Part II will cover:

  • Plaque characterization
  • Procedural planning
  • Post PCI optimization

The webinar will be hosted by Joost Daemen, MD, PhD, senior interventional cardiologist, and Jurgen Ligthart and Karen Witberg, percutaneous imaging specialists.

 Who should attend?

The ACIST HDi® Advanced IVUS training program is designed for physicians who want to further develop their intravascular ultrasound skills with a specific focus on image interpretation using the HDi IVUS high definition imaging technology. It provides an excellent opportunity for physicians who have no HDi IVUS experience or who would like to expand their experience and area of application.

For further information please click here:  ACIST HDi Advanced IVUS Webinar – Erasmus MC – 22 April 2021

 We are excited about hosting Part II of this webinar and hope you are equally excited about the opportunity this brings to your customers.

Best regards,

Olivera Kotevska

Clinical Program Manager EMEA

m: +49 172 6890952


Distributor Highlight

Distributor Highlight – Al Umnia 

The final quarter of 2020 was an exciting time for ACIST in Europe as we unveiled our new long-awaited non-hyperemic index dPR– our adenosine-free predictor of ischemia – which now sits alongside Pd/Pa and FFR on our RXI consoles. We’re receiving great feedback from European customers who have started to use dPR, which is in line with the experience of the one distributor who already had dPR for over a year – Al Umnia, our partner in the United Arab Emirates (UAE).

Al Umnia launched RXI and Navvus in 2016 and quickly established the technology. Thanks to a great deal of hard work from their two FFR experts, Ashok Murugesan and Davis Chittilappilly, and the expert guidance of Director Rami Abusamra, they placed 18 systems in the first two years in UAE’s 28 cath labs, and quickly took a sizeable share of the crowded UAE physiology market. Ashok estimates that the 320 Navvus used in 2019 amounted to 35% of the market.

Building on that success, and as dPR did not require CE mark or FDA approval in UAE,  we were able to launch in June 2019. As we know, the background is that a significant number of physicians remain true-believers in FFR, but iFR has made inroads into the market in recent years, with many physicians persuaded to preference the greater ease and speed of the non-hyperemic indices over the superior diagnostic accuracy of FFR. Faced with this reality, Al Umnia carefully identified the 10 centres where interest in adenosine-free indices was greatest and upgraded those consoles.

One year on, we can see that despite the lack of prospective dPR data, the well-established class-effect of the non-hyperemic indices has meant that ACIST dPR has been rapidly adopted by physicians on both sides of the hyperemia divide in UAE, whichever way they lean. ACIST dPR allows physicians to assess ischemia in the quickest possible way, while enjoying the proven benefits of our rapid-exchange Navvus microcatheter. Minimal training is required for new users. After equalization, Navvus slides into position on the guidewire and at the touch of a single button, the console instantly gives you the dPR value.

 In the literature, the established cut-off of for dPR is 0.89 but Ashok reports that most UAE physicians are using a  “hybrid”  approach and opting for FFR if the dPR result is in the 0.88-0.92 range.  In terms of case numbers, Al Umnia report, in the 17 months since the launch, 115 dPR-only cases in which the clinical decision was made without FFR. They have also done a further 265 cases in which both dPR and FFR were measured, either due to a dPR value close to the cut-off, or because of the physician’s preference for FFR. These numbers show that even when they intend to proceed to FFR, it takes hardly any time for a physician to add a dPR value to aid the assessment of lesion severity and ischemia. In the last month or two, the whole procedure has now been made even more seamless with Navvus II.

Feedback in UAE has generally been excellent – physicians appreciate the quick and easy one-touch measurement and instant calculation without the added inconvenience and cost of adenosine. Our unique BeatCheck™ feature is also winning plaudits. According to Ashok, physicians feel that BeatCheck™ “gives complete confidence” regarding the accuracy of the measurement. If there is any doubt, the measurement can be repeated in a matter of seconds.

You can watch Rami Abusamra and Ashok Murugesan talk about their experience in this video: Al Umnia – Video

Finally, a word of congratulations to Al Umnia for their success in launching dPR and their continued commitment to the ACIST product portfolio. We look forward to hearing more positive feedback and more success stories as more of our distributor partners launch dPR in their respective markets.

Mark Green

Business Manager – EMEAI


2021 EMEA Distributor Meeting

To all our valued partners,

Athens, Greece. That’s where the ACIST 2021 Global Distributor Meeting was going to take place. We were excited to meet with you again in the historic city and capital of Greece, one of the world’s oldest cities. Unfortunately, it didn’t happen and we all know why. We decided to move to a global 2021 virtual meeting, only to soon realize that Mexico has breakfast when Australia sleeps when India has dinner. It was not possible to cut through all time zones and have a virtual livestreaming where all of you could join.  But did that stop us? No!

Inge De Borger, Mark Green and Frits Kramer, together with our European Marketing Team, went local and hosted a virtual meeting for all EMEA distributors in early February 2021. The EMEA territory spans 30 distributor countries and more than 80 partners joined the meeting, with new updates and clinical information shared across all product modalities. The virtual Distributor Meeting was a big success, but we missed not having everyone there and we hope to see all of you again in person next year at the 2022 Distributor Meeting!

We encourage everyone to review the 2021 EMEA Distributor Meeting content that is now available in the folder ‘Training |2021 DSM(for internal use only).

Best regards,

Marilene den Exter Blokland




Skip to content